Controlled trial of RSV, herbs or placebo as adjuvants to complete resection of squamous cell lung cancer.
152 completely resected patients with high or intermediate differentiated squamous cell lung cancer were randomized to receive 6 months adjuvant therapy with RSV (1, 2-diphenyl-alpha beta-diketone) herbs or placebo. No significant differences were observed in duration of survival or relapse rates between the three groups.
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000447:Aldehydes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003718:Denmark; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010658:Phenylglyoxal / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use; D010946:Plants, Medicinal; D011897:Random Allocation
D000447:Aldehydes; D000970:Antineoplastic Agents; D010936:Plant Extracts; D010658:Phenylglyoxal; C006697:benzil